iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Women & HCV at AASLD. HCV screening for pregnant women. Routine HCV screening required for elimination.
 
 
  "....current screening & treatment policies would not meet WHO's 2030 elimination targets in the US....We need to implement universal screening of all adults in different subpopulations to meet the target of 90% diagnosis by 2030....no screening & treatment policy will be able to achieve 65% reduction in liver related deaths in any of the US states....only universal screening at a rate of 80% will resulting maximum of up to 40% reduction...."
 
CDC & USPTF:
CDC is augmenting previous guidance with two new recommendations: 1) hepatitis C screening at least once in a lifetime for all adults aged ≥18 years, except in settings where the prevalence of HCV infection is <0.1% and The American College of Obstetricians and Gynecologists (ACOG) is actively reviewing the new guidance from the CDC and USPSTF......https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/04/screening-for-hepatitis-c-virus-infection
 
-------------------
 
Low adherence to infant HCV testing guidelines among pregnant women with HCV cirrhosis - (11/16/20)
 
Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir - (12/04/20)
 
A study of therapy for hepatitis C in pregnancy with Sofosbuvir/Velpatasvir in Australia - (12/08/20)
 
WOMEN AND THE 2019 HEPATITIS C CASCADE OF CARE: FINDINGS FROM THE BC-HEPATITIS TESTERS COHORT - (11/28/20)
 
COST-EFFECTIVENESS OF ANTENATAL RESCREENING AMONG PREGNANT WOMEN FOR HEPATITIS C IN THE UNITED STATES (11/20/20)
 
NAFLD AND ALCOHOL-RELATED LIVER DISEASE ARE PRIMARY DRIVERS OF CURRENT AND FUTURE CAUSES OF CIRRHOSIS AMONG WOMEN IN NORTH AMERICA - (12/03/20)
 
Breastfeeding Linked to Lower Chance of Severe Fibrosis in US Women With NAFLD - - (11/24/20)
 
The "Keep It Simple and Safe" Approach to HCV Treatment: Primary Outcomes from the ACTG A5360 (MINMON) Study -(11/19/20)
 
Pregnant Women/Poor outcomes & Neighborhood/Crime/violence/education - Association of Adverse Neighborhood Exposures With HIV Viral Load in Pregnant Women at Delivery - (12/14/20)
 
Infant Outcomes in HIV/Hepatitis B Co-Infected Women Initiating ART in the Promoting Maternal and Infant Survival Everywhere Study - (12/10/20)
 
Safety And HBV Efficacy Of Antiretroviral Therapy In Women With HIV And HBV In The Promoting Maternal And Infant Survival Everywhere Study (PROMISE) - (12/10/20)
 
Safety, Efficacy, and Pharmacokinetic Analysis of Glecaprevir/Pibrentasvir in Pediatric Patients With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection: Part 2 of the DORA Study - (11/13/20)
 
Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C Infection in Children and Adolescents Aged 3 to 17 Years Old Through 24 Weeks Posttreatment - (11/16/20)
 
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adolescents With Chronic Hepatitis C Virus Infection - (11/16/20)
 
Active Drug Use Is Not Associated with Treatment Failure Among PWID Patients With Variable Adherence to HCV Treatment - (11/16/20)
 
COUNTRY AND WHO REGIONAL TRENDS FOR HEPATITIS B VIRUS (HBV) MORTALITY, 1990-2019: AN ANALYSIS OF THE GLOBAL BURDEN OF DISEASE (GBD) STUDY - (11/18/20)
 
Screening & HCV Elimination Determining Feasibility of Hepatitis C Elimination in the United States Using a Simulation Model - (11/16/20)
 
Country and WHO Regional Trends for Hepatitis C Virus (HCV) Mortality, 1990-2019: An Analysis of the Global Burden of Disease (GBD) Study - (11/17/20)

hcv

 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org